PAVM vs. NEPH, PYPD, MHUA, TTOO, LYRA, GCTK, IINN, SSKN, NXGL, and MBOT
Should you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Nephros (NEPH), PolyPid (PYPD), Meihua International Medical Technologies (MHUA), T2 Biosystems (TTOO), Lyra Therapeutics (LYRA), GlucoTrack (GCTK), Inspira Technologies Oxy B.H.N. (IINN), STRATA Skin Sciences (SSKN), NEXGEL (NXGL), and Microbot Medical (MBOT). These companies are all part of the "surgical & medical instruments" industry.
Nephros (NASDAQ:NEPH) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
PAVmed received 189 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 65.79% of users gave PAVmed an outperform vote while only 39.29% of users gave Nephros an outperform vote.
In the previous week, PAVmed had 3 more articles in the media than Nephros. MarketBeat recorded 5 mentions for PAVmed and 2 mentions for Nephros. PAVmed's average media sentiment score of 0.37 beat Nephros' score of -0.45 indicating that Nephros is being referred to more favorably in the media.
41.1% of Nephros shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 4.1% of Nephros shares are owned by company insiders. Comparatively, 12.6% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Nephros has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
PAVmed has a consensus price target of $21.00, suggesting a potential upside of 854.55%. Given Nephros' higher probable upside, analysts plainly believe PAVmed is more favorable than Nephros.
Nephros has a net margin of -11.06% compared to Nephros' net margin of -2,617.25%. Nephros' return on equity of 0.00% beat PAVmed's return on equity.
Nephros has higher revenue and earnings than PAVmed. Nephros is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.
Summary
Nephros and PAVmed tied by winning 8 of the 16 factors compared between the two stocks.
Get PAVmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
